NanoString Technologies, Inc. (NASDAQ:NSTG) had its price target cut by Robert W. Baird from $14.00 to $12.00 in a research report report published on Friday. They currently have an outperform rating on the biotechnology company’s stock.

Several other research firms have also weighed in on NSTG. Zacks Investment Research lowered shares of NanoString Technologies from a hold rating to a sell rating in a report on Tuesday, October 17th. BidaskClub lowered shares of NanoString Technologies from a sell rating to a strong sell rating in a report on Friday, July 28th. Cowen and Company reiterated a buy rating and issued a $20.00 target price on shares of NanoString Technologies in a report on Thursday, September 28th. Janney Montgomery Scott lowered shares of NanoString Technologies from a buy rating to a neutral rating in a report on Thursday, October 12th. Finally, ValuEngine lowered shares of NanoString Technologies from a hold rating to a sell rating in a report on Thursday, July 13th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $17.25.

NanoString Technologies (NASDAQ:NSTG) traded up $0.53 during trading hours on Friday, reaching $8.32. 259,496 shares of the company’s stock traded hands, compared to its average volume of 408,915. The company has a current ratio of 4.22, a quick ratio of 3.74 and a debt-to-equity ratio of 0.93. NanoString Technologies has a 12 month low of $7.32 and a 12 month high of $23.45.

NanoString Technologies (NASDAQ:NSTG) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. The company had revenue of $27.02 million for the quarter, compared to analyst estimates of $26.27 million. NanoString Technologies had a negative net margin of 44.24% and a negative return on equity of 227.21%. NanoString Technologies’s revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.51) EPS. equities analysts expect that NanoString Technologies will post -2.26 EPS for the current fiscal year.

WARNING: “Robert W. Baird Cuts NanoString Technologies, Inc. (NSTG) Price Target to $12.00” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/robert-w-baird-cuts-nanostring-technologies-inc-nstg-price-target-to-12-00/1683613.html.

Several hedge funds have recently modified their holdings of NSTG. Bank of Montreal Can lifted its holdings in shares of NanoString Technologies by 3,731.4% in the 2nd quarter. Bank of Montreal Can now owns 9,387 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 9,142 shares during the last quarter. American International Group Inc. lifted its holdings in shares of NanoString Technologies by 7.4% in the 1st quarter. American International Group Inc. now owns 9,153 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 634 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of NanoString Technologies by 16.6% in the 1st quarter. Bank of America Corp DE now owns 11,404 shares of the biotechnology company’s stock worth $227,000 after acquiring an additional 1,627 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of NanoString Technologies in the 3rd quarter worth approximately $240,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of NanoString Technologies by 25.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,542 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 3,132 shares during the last quarter. Hedge funds and other institutional investors own 93.04% of the company’s stock.

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.